EUCTR2004-000738-34-DE进行中（未招募）不适用
Multinational, randomized, double-blind, double-dummy, comparative study toevaluate the efficacy and safety of telithromycin 25 mg/kg given once daily for 5 or10 days depending on age and previous treatment history versus cefuroxime axetil15 mg/kg, given twice daily for 10 days, in children with acute otitis media
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects =6 months and =59 months of age with AOM;
- •Recent (within the last 72 hours) and rapid onset of AOM signs and symptoms;
- •The presence of MEF on otoscopy indicated by a bulging tympanic membrane;
- •Tympanometry exhibiting the following results:
- •-Type B curve or positive pressure peak curves consistent with the presence of MEF;
- •Otalgia or ear tugging or touching within the last 24H that interferes with or precludes normal activity or sleep;
- •At least 1 of the following clinical findings not specific to AOM: fever, vomiting, diarrhea, anorexia, sleep disturbance, or irritability;
- •Tympanocentesis performed per protocol;
- •Informed consent must be obtained in writing at enrollment into the study, from the child’s parent/legally authorized representative. The parent/legally authorized representative has agreed to provide follow-up information and arrange for all scheduled visits, even in the event that study medication is discontinued.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Uncertain diagnosis of AOM or signs and symptoms of AOM that would make the subject a candidate for observation and analgesic therapy with observation for 2-3 days;
- •Otorrhea or tympanostomy tube present in either ear at study entry;
- •Otitis externa;
- •Down syndrome, cleft palate, craniofacial disorders, cystic fibrosis/mucoviscidosis, immotile cilia syndrome, congenital immunodeficiency or acquired immunodeficiency syndrome with <25% CD4 count or requiring prophylaxis for Pneumocystis jiroveci (carinii) or requiring treatment for an opportunistic infection;
- •Known congenital prolonged QT syndrome;
- •Uncorrected hypokalemia (=3 mmol/L [mEq/L]), hypomagnesemia (based on laboratory assessment), bradycardia (<50 bpm);
- •Myasthenia gravis;
- •Known impaired renal function, as shown by the creatinine clearance =25 mL/min
- •Any medical condition (including development disorders, visual disroders, or ocular anormalities) that, in the opinion of the investigator, would interfere with implementation of the protocol or interpretation of the study results;
- •The subject:
- •-Is being treated with drugs not permitted by the study protocol ie, cisapride, pimozide, astemizole, terfenadine, ergotamine, dihydroergotamine, class IA (eg, quinidine and procainamide) or Class III (eg, dofetilide) antiarrhythmic agents, simvastatin, lovastatin or atorvastatin;
- •-Is currently being treated with systemic antibacterials or has been treated with systemic antibacterials within 5 days prior to enrollment;
- •-Has been treated with any investigational medication within the last 30 days; or
- •-Has been treated with rifampicin, phenytoin, carbamazepine, or St. John’s wort within the last 2 weeks.
- •History of hypersensitivity or intolerance to macrolides, penicillins, or cephalosporins;
- •Previous enrollment in this study or previous treatment with telithromycin;
- •Children of the investigator or subinvestigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the protocol
研究者
相似试验
进行中（未招募）
不适用
TELI CAP - Telithromycin in children with mild to moderate community-acquired pneumoniaCommunity acquired pneumoniaMedDRA version: 17.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862EUCTR2014-002867-13-Outside-EU/EEASanofi-aventis210
进行中（未招募）
不适用
TELI COM - Telithromycin in Children With Otitis MediaOtitis Media, SuppurativeOtitis Media, PurulentMedDRA version: 17.1Level: LLTClassification code 10033092Term: Otitis media suppurativeSystem Organ Class: 100000004862EUCTR2014-004637-47-Outside-EU/EEASanofi-aventis1,500
进行中（未招募）
不适用
TELI TON - Telithromycin in TonsillitisTonsillitis PharyngitisMedDRA version: 17.1Level: PTClassification code 10049140Term: PharyngotonsillitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-004630-26-Outside-EU/EEASanofi-aventis760
进行中（未招募）
1 期
A multinational, randomized, double-blind, double-dummy, exploratory, parallel-group, dose-ranging phase II study to evaluate the pharmacodynamics, the safety and tolerability, and the pharmacokinetics of several intravenous regimens of the factor Xa inhibitor otamixaban (XRP0673), in comparison to intravenous unfractionated heparin, in subjects undergoing non-urgent Percutaneous Coronary Intervention. - The SEPIA-PCI TrialPatients with coronary heart disease who will be undergoing non-urgent Percutaneous Coronary Intervention (PCI)EUCTR2004-000904-41-SKAventis Pharmaceuticals Inc.930
进行中（未招募）
1 期
A multinational, randomized, double-blind, double-dummy, exploratory, parallel-group, dose-ranging phase II study to evaluate the pharmacodynamics, the safety and tolerability, and the pharmacokinetics of several intravenous regimens of the factor Xa inhibitor otamixaban (XRP0673), in comparison to intravenous unfractionated heparin, in subjects undergoing non-urgent Percutaneous Coronary Intervention. - The SEPIA-PCI TrialPatients with coronary heart disease who will be undergoing non-urgent Percutaneous Coronary Intervention (PCI)EUCTR2004-000904-41-ESAventis Pharmaceuticals Inc.930